Metabolism Assays Market worth $2.1 billion by 2028

Metabolism Assays Market in terms of revenue was estimated to be worth $1.4 billion in 2023 and is poised to reach $2.1 billion by 2028, growing at a CAGR of 7.8% from 2023 to 2028 according to a new report by MarketsandMarkets™. The growth of this market is majorly driven by rising initiatives by government to promote metabolic & disease research, innovation in metabolism assays technology by integrating with wearable devices, increase in prevalence of metabolic disorders such as diabetes and obesity, and adoption of metabolism assays by fitness and sports industries.

Download an Illustrative overview:

North America dominates the global metabolism assay market.

Based on the region, the metabolism assay market is segmented into North America, Europe, Asia Pacific, and Rest of the World. North American market is driven by well-established pharmaceutical and biotechnology industry, investments around drug discovery and toxicity testing. The Asia Pacific segment is projected to register the highest CAGR during the forecast period. The presence of a large population base coupled with large patient population and increasing rate of obesity are some of the major factors driving the growth of this regional market.

Metabolism Assays Market Dynamics:


· Increasing funding and investments in metabolic research

· Drug discovery and development

· Rise in prevalence of chronic diseases

· Increased use of metabolism assays in fitness and sports

· Growing demand for personalized medicines


· High cost of metabolism assay analyzers

· Presence of alternative methods and techniques


· Integration with wearable devices

· Growing life science research in emerging economies


· Complexity of assay development

Key Market Players:

Major players in metabolism assays market include Merck KGaA (Germany), Thermo Fisher (US), Abcam Plc. (UK), Agilent Technologies Inc. (US), and Kaneka Eurogentec S.A. (Belgium).

Recent Developments:

· In 2022, Thermo Fisher Scientific, Inc. (US) collaborated with Symphogen (Denmark) and Servier (France) for biopharmaceutical discovery and development laboratories.

· In 2021, Abcam Plc. (UK) acquired BioVision (UK). This acquisition of BioVision represents a compelling strategic fit for Abcam. This will bring greater control over the innovation and distribution of BioVision’s product portfolio and create value through portfolio expansion and leveraging Abcam’s global channels to market.

· In 2021, Agilent Technologies Inc. (US) launched Agilent Seahorse XF HS Miniplate which is the latest addition to Agilent’s range of Seahorse XF platforms, which analyze mitochondrial respiration, glycolysis, and ATP production in live cells, in real-time.

Metabolism Assays Market Advantages:

· Early Drug Discovery: Metabolism assays enable the identification of potential drug candidates by assessing how compounds interact with cellular metabolic pathways. This accelerates the drug discovery process by quickly identifying promising leads and eliminating ineffective compounds.

· Toxicity Screening: These assays are essential for evaluating the safety of drugs and chemicals. They help identify potential toxic effects on cellular metabolism, aiding in the development of safer pharmaceuticals and consumer products.

· Personalized Medicine: Metabolism assays can be used to tailor treatments to individual patients by assessing their unique metabolic profiles. This approach allows for more precise and effective therapeutic interventions.

· Disease Mechanism Understanding: Researchers can gain insights into the metabolic dysregulations underlying various diseases, including cancer, diabetes, and metabolic disorders. This knowledge is crucial for developing targeted therapies.

· High-Throughput Capabilities: Automation and high-throughput screening technologies enable the rapid analysis of a large number of compounds or samples, significantly increasing research efficiency and productivity.

· Data-Driven Decision-Making: Advances in data analysis and machine learning enable the extraction of valuable insights from metabolism assay data, facilitating informed decision-making in drug development and disease research.

· Reduction in Animal Testing: Metabolism assays offer alternatives to traditional animal testing, contributing to ethical and regulatory considerations in drug development and toxicity assessment.

· Cost Savings: By streamlining drug discovery processes and reducing the likelihood of late-stage drug failures, metabolism assays can lead to substantial cost savings in pharmaceutical research and development.

· Biotechnology Advancements: The metabolism assays market drives innovation in biotechnology, leading to the development of novel assay techniques, reagents, and instrumentation that benefit various areas of life sciences research.

· Interdisciplinary Research: Metabolism assays promote collaboration between researchers in different fields, including biology, chemistry, pharmacology, and informatics, fostering a holistic approach to understanding metabolism and its implications for health and disease.

In summary, the metabolism assays market plays a pivotal role in advancing biomedical research and pharmaceutical development by offering a range of benefits, from accelerating drug discovery to enabling personalized medicine and improving the safety and efficacy of therapeutic interventions.

Request Sample Pages: